ADVISORY, April 11, 2014 (GLOBE NEWSWIRE) --
Concert Pharmaceuticals, Inc. [CNCE], a clinical stage biopharmaceutical company creating novel drugs for CNS disorders, renal disease, inflammation and cancer, will visit the NASDAQ MarketSite in Times Square.In honor of the occasion, Dr. Roger Tung, Chief Executive Officer will ring the Opening Bell. Where: NASDAQ MarketSite – 4 Times Square – 43 rd & Broadway – Broadcast Studio When: Monday, April 14, 2014 – 9:15 a.m. to 9:30 a.m. ET Concert Pharmaceuticals, Inc. Contact: Justine Koenigsberg (781) 860-0045 firstname.lastname@example.org NASDAQ MarketSite: Christine Barna (646) 441-5310 Christine.Barna@nasdaqomx.com Feed Information: Fiber Line (Encompass Waterfront): 4463 Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK Social Media: For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ. For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx. For exciting viral content and ceremony photos visit Tumblr Page: http://nasdaq.tumblr.com/ Webcast: A webcast of the NASDAQ Opening Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx Photos: To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice. About Concert Pharmaceuticals, Inc. [CNCE]: Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel small molecule drugs. This approach starts with approved drugs, advanced clinical candidates or previously studied compounds that have the potential to be improved with deuterium substitution to enhance clinical safety, tolerability and efficacy. The company is developing a broad pipeline targeting CNS disorders, renal disease, inflammation and cancer.